{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:57:12Z","timestamp":1784674632708,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["General Program, 2023J011298"],"award-info":[{"award-number":["General Program, 2023J011298"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2023Y9439"],"award-info":[{"award-number":["2023Y9439"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80067-0","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T12:46:32Z","timestamp":1731933992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhong","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"80067_CR1","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. Avatrombopag: a review in thrombocytopenia. Drugs 81, 1905\u20131913 (2021). Doi: 10.1007\/s40265-021-01613-y.","journal-title":"Drugs"},{"key":"80067_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","volume":"37","author":"M Peck-Radosavljevic","year":"2017","unstructured":"Peck-Radosavljevic, M. Thrombocytopenia in chronic liver disease. Liver Int. 37, 778\u2013793. https:\/\/doi.org\/10.1111\/liv.13317 (2017).","journal-title":"Liver Int."},{"key":"80067_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1365-2036.2008.03674.x","volume":"27","author":"P Witters","year":"2008","unstructured":"Witters, P. et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment. Pharmacol. Ther. 27, 1017\u20131029. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03674.x (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"80067_CR4","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert, C. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3, 3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966 (2019).","journal-title":"Blood Adv."},{"key":"80067_CR5","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","volume":"28","author":"P Gallo","year":"2022","unstructured":"Gallo, P. et al. Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures. World J. Gastroenterol. 28, 4061\u20134074. https:\/\/doi.org\/10.3748\/wjg.v28.i30.4061 (2022).","journal-title":"World J. Gastroenterol."},{"key":"80067_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.14423","volume":"176","author":"LJ Estcourt","year":"2017","unstructured":"Estcourt, L. J. et al. Guidelines for the use of platelet transfusions. Br. J. Haematol. 176, 365\u2013394. https:\/\/doi.org\/10.1111\/bjh.14423 (2017).","journal-title":"Br. J. Haematol."},{"key":"80067_CR7","doi-asserted-by":"publisher","unstructured":"Poordad, F. et al. Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies. Int. J. Hepatol. 2020, 5421632.  https:\/\/doi.org\/10.1155\/2020\/5421632 (2020).","DOI":"10.1155\/2020\/5421632"},{"key":"80067_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley, M. Avatrombopag: first global approval. Drugs 78, 1163\u20131168. https:\/\/doi.org\/10.1007\/s40265-018-0949-8 (2018).","journal-title":"Drugs"},{"key":"80067_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.exphem.2008.04.020","volume":"36","author":"M Fukushima-Shintani","year":"2008","unstructured":"Fukushima-Shintani, M. et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp. Hematol. 36, 1337\u20131342. https:\/\/doi.org\/10.1016\/j.exphem.2008.04.020 (2008).","journal-title":"Exp. Hematol."},{"key":"80067_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","volume":"155","author":"N Terrault","year":"2018","unstructured":"Terrault, N. et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with Chronic Liver Disease and Thrombocytopenia. Gastroenterology 155, 705\u2013718. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.025 (2018).","journal-title":"Gastroenterology"},{"key":"80067_CR11","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/s2352-3026(22)00001-1","volume":"9","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari, H. et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 9, e179\u2013e189. https:\/\/doi.org\/10.1016\/s2352-3026(22)00001-1 (2022).","journal-title":"Lancet Haematol."},{"key":"80067_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann, T. A., Abdulmujeeb, S. & Ehrenpreis, E. D. Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting System (FAERS) database. Aliment. Pharmacol. Ther. 54, 1290\u20131297. https:\/\/doi.org\/10.1111\/apt.16601 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"80067_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak, W. et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br. J. Haematol. 183, 479\u2013490. https:\/\/doi.org\/10.1111\/bjh.15573 (2018).","journal-title":"Br. J. Haematol."},{"key":"80067_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1345\/aph.1P042","volume":"44","author":"SL Corman","year":"2010","unstructured":"Corman, S. L. & Mohammad, R. A. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann. Pharmacother. 44, 1072\u20131079. https:\/\/doi.org\/10.1345\/aph.1P042 (2010).","journal-title":"Ann. Pharmacother"},{"key":"80067_CR15","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel, J. B. et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123, 3887\u20133894. https:\/\/doi.org\/10.1182\/blood-2013-07-514398 (2014).","journal-title":"Blood"},{"key":"80067_CR16","doi-asserted-by":"publisher","first-page":"e35208","DOI":"10.1097\/md.0000000000035208","volume":"102","author":"SK Satapathy","year":"2023","unstructured":"Satapathy, S. K. et al. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure. Med. (Baltim). 102, e35208. https:\/\/doi.org\/10.1097\/md.0000000000035208 (2023).","journal-title":"Med. (Baltim)."},{"key":"80067_CR17","doi-asserted-by":"publisher","unstructured":"Krishnegowda, M. & Rajashekaraiah, V. Platelet disorders: an overview. Blood Coagul Fibrinolysis 26, 479\u2009\u2013491.  https:\/\/doi.org\/10.1097\/01.mbc.0000469521.23628.2d (2015).","DOI":"10.1097\/01.mbc.0000469521.23628.2d"},{"key":"80067_CR18","unstructured":"Food and Drug Administration. (2024, accessed 6 Oct 2024). https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/spl-summaries\/criteria\/393321."},{"key":"80067_CR19","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","volume":"53","author":"DJ Kuter","year":"2022","unstructured":"Kuter, D. J. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 53, 100909. https:\/\/doi.org\/10.1016\/j.blre.2021.100909 (2022).","journal-title":"Blood Rev."},{"key":"80067_CR20","doi-asserted-by":"publisher","unstructured":"Huang, A. et al. Effectiveness and safety of avatrombopag in liver cancer patients with severe thrombocytopenia: real-World data and challenges. J. Oncol. 2022, 9138195. https:\/\/doi.org\/10.1155\/2022\/9138195 (2022).","DOI":"10.1155\/2022\/9138195"},{"key":"80067_CR21","doi-asserted-by":"crossref","unstructured":"PM. C, S D., T M., et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul. 3, 148 (2024).","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"80067_CR22","doi-asserted-by":"crossref","unstructured":"W. Z, X Z., S Y., et al. Adverse event profiles of Adalimumab in children: a disproportionality analysis. Pharmaceuticals (Basel) 17, 785 (2024).","DOI":"10.3390\/ph17081028"},{"key":"80067_CR23","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2023","unstructured":"Shu, Y. et al. Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. 12, 3365\u20133375. https:\/\/doi.org\/10.1002\/cam4.5062 (2023).","journal-title":"Cancer Med."},{"key":"80067_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown, E. G. Using MedDRA: implications for risk management. Drug Saf. 27, 591\u2013602. https:\/\/doi.org\/10.2165\/00002018-200427080-00010 (2004).","journal-title":"Drug Saf."},{"key":"80067_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"80067_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"80067_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"80067_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1999.10474456","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. 53:177\u2013190 https:\/\/doi.org\/10.1080\/00031305.1999.10474456 (1999).","journal-title":"53:177\u2013190"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80067-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:16:29Z","timestamp":1732241789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80067-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80067"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80067-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. The datasets used for the current study are publicly available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28488"}}